John H. Baird

1.9k total citations
34 papers, 374 citations indexed

About

John H. Baird is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, John H. Baird has authored 34 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 8 papers in Immunology. Recurrent topics in John H. Baird's work include CAR-T cell therapy research (22 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immune Cell Function and Interaction (4 papers). John H. Baird is often cited by papers focused on CAR-T cell therapy research (22 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immune Cell Function and Interaction (4 papers). John H. Baird collaborates with scholars based in United States, Singapore and Taiwan. John H. Baird's co-authors include Haowei Song, Babak Razani, Fong‐Fu Hsu, Clay F. Semenkovich, Trey Coleman, John Turk, Li Yin, Katsuhiko Funai, Irfan J. Lodhi and Jason Gotlib and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

John H. Baird

26 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John H. Baird United States	9	133	123	108	60	59	34	374
Paula Saavedra-García United Kingdom	13	376 2.8×	62 0.5×	57 0.5×	33 0.6×	114 1.9×	18	531
Alysia Kern Lovgren United States	6	171 1.3×	69 0.6×	84 0.8×	53 0.9×	14 0.2×	6	501
Geun-Young Kim South Korea	8	114 0.9×	73 0.6×	45 0.4×	20 0.3×	27 0.5×	11	355
Janice M. Kraniak United States	11	222 1.7×	60 0.5×	104 1.0×	11 0.2×	40 0.7×	15	497
Xiaojuan Zhang China	11	106 0.8×	26 0.2×	74 0.7×	13 0.2×	36 0.6×	31	336
Latoya E. Campbell United States	11	219 1.6×	89 0.7×	114 1.1×	33 0.6×	30 0.5×	14	389
Chunting Tan China	12	195 1.5×	35 0.3×	31 0.3×	56 0.9×	64 1.1×	22	470
John Stoops United States	11	247 1.9×	48 0.4×	48 0.4×	19 0.3×	161 2.7×	16	493
Blandine Secco Canada	10	230 1.7×	170 1.4×	15 0.1×	35 0.6×	76 1.3×	12	453
Susanne Grond United States	14	168 1.3×	157 1.3×	16 0.1×	184 3.1×	50 0.8×	27	531

Countries citing papers authored by John H. Baird

Since Specialization

Citations

This map shows the geographic impact of John H. Baird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Baird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Baird more than expected).

Fields of papers citing papers by John H. Baird

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Baird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Baird. The network helps show where John H. Baird may publish in the future.

Co-authorship network of co-authors of John H. Baird

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Baird. A scholar is included among the top collaborators of John H. Baird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Baird. John H. Baird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Srinagesh, Hrishikesh K., Anne Marijn Kramer, John H. Baird, et al.. (2025). Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome. Blood Cancer Discovery. 7(2). 225–233.

Mei, Matthew, Joycelynne Palmer, Hun Ju Lee, et al.. (2025). Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma. HemaSphere. 9(5). e70126–e70126.

Xiao, Annie, Lu Chen, Matthew Mei, et al.. (2025). Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leukemia & lymphoma. 66(12). 2260–2268.

Baird, John H., Lu Chen, Joo Y. Song, et al.. (2024). Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease. Blood. 144(Supplement 1). 3127–3127.

Budde, Lihua E., John H. Baird, Lu Chen, et al.. (2024). PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.. Journal of Clinical Oncology. 42(16_suppl). 6534–6534. 1 indexed citations

Nie, Esther H., Yi‐Jiun Su, John H. Baird, et al.. (2024). Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Advances. 8(6). 1474–1486. 6 indexed citations

Ghobadi, Armin, Caron A. Jacobson, Joseph P. McGuirk, et al.. (2024). Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.. Journal of Clinical Oncology. 42(16_suppl). TPS7085–TPS7085. 1 indexed citations

Nie, Esther H., Yi‐Jiun Su, John H. Baird, et al.. (2024). Clinical and Neuroradiological Features of Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma (MCL) (S23.007). Neurology. 102(7_supplement_1). 1 indexed citations

Kramer, Anne Marijn, Yiyun Chen, Hrishikesh K. Srinagesh, et al.. (2024). CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Blood. 144(Supplement 1). 911–911.

10.

Strouse, Christopher, Umar Farooq, Roni Shouval, et al.. (2024). Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 144(Supplement 1). 609–609.

11.

Ong, Shin Yeu, Matthew Mei, Leslie Popplewell, et al.. (2023). Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma. American Journal of Hematology. 98(11). 1751–1761. 17 indexed citations

12.

Baird, John H., Pim Mutsaers, Jeremy S. Abramson, et al.. (2023). Abstract CT129: Trial in progress: ATHENA-1 - a phase 1, open-label, first-in-human study to assess safety and tolerability of REGN5837 in combination with odronextamab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas. Cancer Research. 83(8_Supplement). CT129–CT129. 2 indexed citations

13.

Baird, John H., Joo Y. Song, Geoffrey Shouse, et al.. (2023). CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL). Blood. 142(Supplement 1). 4840–4840. 1 indexed citations

14.

Srinagesh, Hrishikesh K., John H. Baird, Neha Agarwal, et al.. (2023). CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature. Blood. 142(Supplement 1). 4839–4839. 3 indexed citations

15.

Vijenthira, Abi, et al.. (2023). COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies. American Society of Clinical Oncology Educational Book. 43(43). e390778–e390778. 4 indexed citations

16.

Craig, Juliana, John H. Baird, Jay Y. Spiegel, et al.. (2020). Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. Blood. 136(Supplement 1). 32–33. 4 indexed citations

17.

Baird, John H. & Jason Gotlib. (2018). Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. Current Hematologic Malignancy Reports. 13(5). 407–416. 17 indexed citations

18.

Baird, John H., Srđan Verstovšek, Tracy I. George, et al.. (2017). Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis. Blood. 130. 2909–2909. 1 indexed citations

19.

Baird, John H. & Jason Gotlib. (2016). A Stimulating Case of Leukocytosis. The Hematologist. 13(6).

20.

Lodhi, Irfan J., Li Yin, Katsuhiko Funai, et al.. (2012). Inhibiting Adipose Tissue Lipogenesis Reprograms Thermogenesis and PPARγ Activation to Decrease Diet-Induced Obesity. Cell Metabolism. 16(2). 189–201. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact